Literature DB >> 15331069

The potential role of genes in nonalcoholic fatty liver disease.

C P Day1.   

Abstract

Although most people with obesity and type 2 diabetes will have steatosis, only a minority will ever develop nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Family studies suggest that genetic factors are important in disease progression, although dissecting genetic factors playing a role in NASH and fibrosis from those influencing the development established risk factors is difficult. Several approaches can be used to look for genetic factors playing a role in nonalcoholic fatty liver disease (NAFLD). In the future, genome-wide single nucleotide polymorphism (SNP) scanning of cases and controls may become feasible. To date, however,studies have relied on candidate gene, case control, allele association methodology. Recent, and as yet preliminary, studies have reported associations between steatosis severity, NASH, and fibrosis with genes whose products are involved in lipid metabolism,oxidative stress, and endotoxin-cytokine interactions. If confirmed,these associations will enhance understanding of disease pathogenesis,and accordingly, the ability to design effective therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331069     DOI: 10.1016/j.cld.2004.04.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs.

Authors:  Andreas Crameri; Jutta Marfurt; Kefas Mugittu; Nicolas Maire; Attila Regös; Jean Yves Coppee; Odile Sismeiro; Richard Burki; Eric Huber; Daniel Laubscher; Odile Puijalon; Blaise Genton; Ingrid Felger; Hans-Peter Beck
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

2.  Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report.

Authors:  Hiroki Oikawa; Chihaya Maesawa; Ryo Sato; Kanta Oikawa; Hiroyuki Yamada; Seizo Oriso; Sadahide Ono; Akiko Yashima-Abo; Koji Kotani; Kazuyuki Suzuki; Tomoyuki Masuda
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

3.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

Review 4.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

5.  Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis.

Authors:  Melanie Kahle; Marion Horsch; Barbara Fridrich; Anett Seelig; Jürgen Schultheiß; Jörn Leonhardt; Martin Irmler; Johannes Beckers; Birgit Rathkolb; Eckhard Wolf; Nicole Franke; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susanne Neschen
Journal:  Mol Metab       Date:  2013-08-03       Impact factor: 7.422

Review 6.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

7.  Heritability of nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Manuel A Celedon; Joel E Lavine; Rany Salem; Nzali Campbell; Nicholas J Schork; Masoud Shiehmorteza; Takeshi Yokoo; Alyssa Chavez; Michael S Middleton; Claude B Sirlin
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

8.  The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat.

Authors:  Emanuele Miraglia del Giudice; Anna Grandone; Grazia Cirillo; Nicola Santoro; Alessandra Amato; Carmine Brienza; Piera Savarese; Pierluigi Marzuillo; Laura Perrone
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.